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Objective/background: Detection of mutations in the quinolone resistance-determining
region (QRDR) of the gyrA gene could determine resistance to fluoroquinolone antitubercu-
losis drugs. The aim of this study was to detect mutations in QRDRs.
Methods: From 184 clinical isolates of Mycobacterium tuberculosis, ofloxacin resistance was
proven in 42 isolates using the proportion method. The molecular basis of resistance to
ofloxacin were investigated by the determination of mutations in the QRDR region of the
gyrA gene. Extracted DNA fragments of 194 bp from the gyrA gene were amplified and an
automatic DNA sequencer was used for the sequencing process.
Results: Molecular genetic analysis of 42 resistant M. tuberculosis strains demonstrated
that they belong to Principal Genetic Group (PGG) 1 in 19 cases (45.2 ± 10.9%), to PGG2 in
15 cases (35.7 ± 10.5%), and to PGG3 in eight cases (19.0 ± 8.4%). Isolates from PGG1 were
dominant among resistant isolates (P < .05). It was found that 24 (57%) resistant isolates
carried mutations at codon 94 with five different amino acid changes: D94A (n = 11),
D94G (n = 3), D94T (n = 4), D94A (n = 4), and D94Y (n = 2). The remaining 18 (43%) isolates
had mutations in codon A90V (GCG? GTG) and S91P (TCG? CCG). Five isolates had two
mutations in codons 90 and 94. There was no difference between mutations at these twoof Medical
300 I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 5 ( 2 0 1 6 ) 2 9 9 –3 0 5codons in resistant isolates of the two countries (P < .001). There was no polymorphism
observed in codon 95 in any of the ofloxacin-susceptible isolates.
Conclusion: It was concluded that the determination of nucleotide sequences of QRDRs
can be used as a molecular test for the rapid detection of ofloxacin resistance. Furthermore,
frequencies in gyrA codons in Belarus and Iran were similar, therefore it is not of geograph-
ical concern for the two countries.
 2016 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
The incidence of resistance to isoniazid and rifampicin
(multidrug-resistant tuberculosis; MDR-TB), is a worldwide
problem [1,2].
Fluoroquinolones are the first new antimycobacterial
drugs to be available since the discovery of rifampin against
Mycobacterium tuberculosis and are part of the treatment rec-
ommended for MDR-TB. The increasing use of quinolones in
the community can lead to decreased quinolone susceptibil-
ity in M. tuberculosis. This raises interest in the mechanisms
of resistance in this organism [2–5].
Spontaneous mutations in chromosomal genes are the
main cause of drug resistance in M. tuberculosis. They may
have produced the selection of resistant strains during subop-
timal drug therapy [6].
The most important mechanism of fluoroquinolone resis-
tance in M. tuberculosis is mutations in the fluoroquinolone-
resistance determining region of the gyrA gene. To determine
the mutations in the fluoroquinolone-resistance determining
region a marker could be used for the detection of fluoro-
quinolone resistance in M. tuberculosis [7].
The MDR form is produced by sequential accumulation of
mutations in different genes involved in the resistance to
individual drugs due to inappropriate treatment [4,5].
In Iran, the incidence of TB cases (all forms) in 2008–2009
was 23 in 100,000 individuals and mortality was three
deaths/100,000 population/y [3–5].
The natural drug resistance of M. tuberculosis is an impor-
tant obstacle for the treatment and control of TB. This resis-
tance has traditionally been attributed to the unusual
multilayer cell envelope and active multidrug efflux pumps
[5–8].
Methods for the detection of drug resistance include both
phenotypic and genotypic methods. Phenotypic methods
might be closer to implementation on a routine basis in
mycobacteriology laboratories. Genotypic methods have the
advantage of a rapid test, no need for growth of bacterium,
the possibility of direct application in clinical samples, and
the feasibility of automation. However, to date, not all molec-
ular mechanisms of drug resistance are known very well [6].
The aim of this study was to assess the susceptibility of
quinolones among M. tuberculosis strains and to survey the
putative mutations associated with quinolone resistance in
the a-subunit of the gyrA gene in some clinical strains of M.
tuberculosis isolated from Iranian and Belarusian patients.Materials and methods
Patients
One hundred and forty patients from Belarus and 44 patients
from Iran were entered in the study as per World Health
Organization recommendation methods [2,5,8].
M. tuberculosis isolates
Patient samples were cultured on Lo¨wenstein–Jensen med-
ium (Merck KGaA 64271, Heidelberg, Germany). Sputum col-
lection and inoculation was carried out in the National
Reference Laboratory of the Research Institute for
Pulmonology and Phthisiology of Belarus and the National
Research Institute of Tuberculosis and Long Disease of Iran.
M. tuberculosis H37Rv was included as a control strain in
the drug-susceptibility testing and molecular experiments.
Drug susceptibility testing
Susceptibility testing was accomplished using the absolute
concentration method on Lo¨wenstein–Jensen medium. A
microbial suspension containing 5  108 organisms/mL was
prepared as per McFarland turbidity and was diluted to 1:10,
and 0.2 mL was then added to the Lo¨wenstein–Jensen med-
ium. The culture tubes were incubated at 37 C, and growth
was achieved after 3–4 weeks of incubation. An isolate was
considered resistant when bacterial growth occurred in the
presence of a concentration of 2 lg/mL ofloxacin by the
BACTEC system (MGIT 960; Becton Dickinson Microbiology
Systems, Sparks, Maryland, USA) in a Level III laboratory.
Bacterial genomic DNA isolation
Bacterial genomic DNA was extracted using the Genomic
DNA Purification Kit (Genomic DNA Purification Kit (#K0512
Fermentas, Vilnius, Lithuania)) according to the manufac-
turer’s instructions. Furthermore, Chelex-100 method was
used briefly by heating of two colonies dissolved in Tris–acet-
ate–EDTA (TAE) buffer in 5% the Chelex 100 Resin (Bio-Rad,
Berkeley, CA, USA; part 143-.3832, 100–200 mesh Chelex,
sodium form) for 45 min in 95 C followed by centrifugation
for 15 min three times at 21952g. This is because Chelex 100
would interfere with the polymerase chain reaction (PCR)
reaction and needs to be totally removed [9].
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Amplification of genome fragments of the gyrA gene of clini-
cal isolates of M. tuberculosis was accomplished as following
for PCR and the subsequent sequencing method. Detection
of the 194-bp DNA fragment of the gyrA gene was performed
by PCR amplification with oligonucleotide primers gyrA-F: 50-
CGATTCCGGCTTCCGCCCGG-30 and gyrA-R: 50CCGGTGGGTCA
TTGCCTGGCG-30. The primers produce a product of 194 bp
at an annealing temperature of 68 C [10].
The PCR reaction was performed in a volume of 50 lL of a
reaction mixture containing 10-lL purified DNA, 5-lL 10  Taq
Buffer (containing [NH4]2SO4 and 20 mM MgCl2), 1 lL of
seoxynucleotides 10 mM each (Fermentas R0192 Fermentas,
Vilnius, Lithuania), 1 U Taq polymerase, and 25 pmols of each
primer. PCR cycles were as follows: one cycle at 95 C for
4 min, 40 cycles started at 94 C for 40 s, 68 C for 1 min, 72 
C for 20 s, with a final cycle at 72 C for 10 min.
Gel electrophoresis method was used for the detection of
gene bands on agarose gel. A 10-lL aliquot of the PCR product
was used for electrophoresis reaction for 1.5 h on 1.5%
agarose gel in 1 TAE buffer at 80 V. A DNA marker (50-bp
Fermentas) was used for size determination of the bands.
The agarose gel was prepared by TAE buffer with the addition
of ethidium bromide.
Amplified 194-bp bands of the gyrA gene were extracted
from the gel by a kit (Fermentas, K0513, Vilnius, Lithuania)
according to manufacturer’s instruction. The concentration
of purified DNA was measured by a Nucleic Acid analyzer
(DU 730, Biochrom WPA Biowave DNA Life Science UV/visible
spectrophotometer).
Principal genotypic groups among the isolates were deter-
mined as mentioned in a previous study [11].
DNA sequencing
DNA fragments of 194 bp from the gyrA gene were amplified
in a Rotor-Gene (RG-3000; Corbett Research Inc., VA, USA)
and Personal Thermo Cycler MJ MiNi (Bio-Rad) with a
Thermo-Sequenase Cy5 Dye Terminator Sequencing Kit (GE
Healthcare, Buckinghamshire, UK; 27-2682-01). Sequencing
was performed using a DNA sequencer by Applied Biosystems
(3130; Applied Biosystems, Foster City, CA, USA) apparatus.
Results
Patient’s characteristics
From 140 patients of Belarus harboring active TB, 95 patients
(68%) were men and 45 (32%) were women; thus the male/
female ratio was 2:1. Furthermore, 65 (46.5%) of the patients
had primary TB and 75 (52%) had a secondary form. These
patients originated from Minsk and other regions of Belarus
(Brest, Magiliev, Gomel, Gorodna, and Vitebsk) and were
admitted to the National Reference Laboratory of the
Research Institute of Pulmonology and Phthisiology of
Belarus.
However, samples from 44 Iranian patients that were
admitted to the Mycobacteriology Research Center of theNational Research Institute of Tuberculosis and Lung Disease,
Tehran, Iran, were undergoing the proportion method of drug
resistance. From 44 patients, 24 patients were men and 20
were women.
Results of drug susceptibility testing
From the 184 clinical isolates of M. tuberculosis from both
countries, 42 isolates consisting of 20 strains from Iran and
22 isolates from Belarus were selected. All of them proved
resistant to 2-lg/mL ofloxacin (Apotex Corp. Canada) by drug
susceptibility testing. Furthermore, eight MDR (susceptible to
ofloxacin) and two pan-susceptible strains were randomly
selected and used in this work.
DNA purification and PCR
DNA extraction by Chelex 100 was the best approach for
purification and maintenance of DNA over a long period of
time (over 5 years).
PCR method using primers for amplification of 194-bp
amplicon can further detect all resistant and susceptible iso-
lates which were identified with conventional methods.
Sequencing of the QRDR part of gyrA gene in resistant clinical
isolates of M. tuberculosis
Forty-two clinical isolates were studied for the molecular
basis of drug resistance to fluoroquinolone drugs. The study
was based on the detection of the nucleotide sequence of
QRDRs of the gene encoding the a-subunit of DNA gyrase
(gyrA) by a sequencing method.
A frequency of amino acid and nucleotide substitutions in
codons 90, 91, and 94 gene gyrA was determined in resistant
isolates by sequencing (Table 1, Fig. 1).
It was revealed that a mutation in codon 94 (GAC to AAC,
GGC, TAC, GCC, or ACT) was a frequent one as it was observed
in 24 (57%) of the 42 resistant isolates. Eighteen (43%) of the
investigated resistant isolates contained mutations in codon
90 (GCG GTG) and five isolates had two simultaneous muta-
tions in codons 90 (GCG GTG) and 94 (GAC CAC) (Tables 1
and 2, Fig. 2). There was no difference between mutations in
resistant isolates of the two countries (P < .001). A mutation
in codon 95 was identified in all MDR (susceptible) and resis-
tant Iranian and Belarusian isolates, but was not observed
among the pan-susceptible isolates. Given that the MDR-
isolates were not resistant to fluoroquinolones, this has
proved that a mutation in this codon is not related to fluoro-
quinolone resistance (Fig. 2).
Our findings confirmed that 26% of isolates belonged to
Principle Genetic Group (PGG) 1. It was assumed that PGG1
being evolutionarily older than other groups and the classifica-
tion referred to strain Beijing in a subgroup of Genetic Group 1.
Discussion
In this study, gyrA mutations were predominantly found to
occur in codons 90, 91, and 94, corroborating the findings of
the other studies [12,13] which is in agreement with previous
Table 1 – Dominant amino acid and nucleotide substitutions in quinolone resistance-determining regions in all resistant
isolates.
Substitutions Samples from Belarus, N = 22, (%) Samples from Iran, N = 20, (%) Total = 42 (%)
A90V (GCG? GTG) 9 (21.4) 7 (16.6) 16 (38.1)
D94A (GAC? AAC) 6 (14.2) 5 (11.1) 11 (26.2)
D94G (GAC? GGC) 1 (2.4) 2 (4.76) 3 (7.14)
D94T (GAC? TAC) 2 (4.76) 2 (4.76) 4 (9.5)
D94A (GAC? GCC) 2 (4.76) 2 (4.76) 4 (9.52)
D94Y (GAC? ACT) 1 (2.4) 1 (2.4) 2 (4.76)
S91P (TCG? CCG) 1 (2.4) 1 (2.4) 2 (4.76)
Note: *P < 0.05.
Fig. 1 – Structure of quinolone resistance-determining region of GyrA protein (codons 89–95) with forward and reverse
primers.
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losis is mostly attributed to the mutations of the gyrA gene
[12,14,15].
Our results demonstrate the relationship between nucleo-
tide sequences in gyrA and the phenotypic susceptibility to
ofloxacin in 42 M. tuberculosis clinical isolates.
Five isolates showed double mutations in codons 90 and
94. In the present study, we reported two patterns of double
mutations in five isolates: three with A90V (GCG? GTG) and
D94A (GAC? AAC) and two with A90V (GCG? ACG) and
D94A (GAC? AAC). Previous reports on double mutations
mainly focused on one kind of codon-90 mutation [13,16,17].
However, the presence of different populations either as
variants of the same isolate or as a mixture of two genetically
independent isolates was shown in this study. It needs to be
mentioned that the double mutants, D94G/D94N, must be
the result of mixed populations as they cannot be present
in the same codon; however, this situation was not detected
in the present study.
In the ofloxacin-resistant M. tuberculosis clinical isolates,
35 of 42 (83.3%) had mutations in the QRDR of the gyrA gene,
and the other had no mutations with a wild-type gyrA
sequence—a finding consistent with those previously report-
ing averages of 80–85% [12,15,19]. Other resistance mecha-
nisms, such as mutations in areas of gyrA outside of the
QRDR, decreased cell-wall permeability to the drug, and efflux
pumps may be accounting for the fluoroquinolone resistance
in fluoroquinolone-resistant isolates without gyrA mutations.
The frequency of the gyrA gene total mutation in the pre-
sent study was similar to those of Cui et al. [12] (89.5%) and
Mokrousov et al. [19] (83%) but higher than those of the Yin
and Yu [15] (73.3%) and Haung et al. [18] (50%) reports.Furthermore, in these ofloxacin-resistant isolates, 25 of 42
(59.5%) had mutations in the codon 94 of the gyrA gene, and
the others had mutations in 90 and 91, which is consistent
with what has been previously reported on fluoroquinolone
resistance [12–17].
The mechanism of fluoroquinolone resistance in M. tuber-
culosis occurs by mutations in DNA gyrase. For this reason, it
is important to detect all mutations in DNA gyrase genes ofM.
tuberculosis and determine the role of these mutations in
fluoroquinolone resistance.
Determination of drug resistance by traditional methods
requires 5–12 weeks because M. tuberculosis is a slow-
growing bacterium. Rapid molecular methods facilitate the
diagnosis of resistance, including MDR-TB and extensively
drug-resistant TB, which can occur faster than with conven-
tional susceptibility testing.
The most widely used rapid molecular method to
detect fluoroquinolone resistance was PCR and DNA
sequencing. More rapid testing methods included multiplex
allele-specific PCR, PCR single-strand conformation polymor-
phism/multiplex PCR amplimer conformation, pyrosequenc-
ing, denaturing high performance liquid chromatography,
real-time PCR (locked nucleic acid-PCR), and GenoType
MTBDR line probe [12,15–19].
The possible roles of the mutations in QRDR and their rela-
tionships with fluoroquinolone resistance were studied. Our
results showed that the polymorphism at codon 95, encoding
either serine or threonine, did not have a significant impact
on fluoroquinolone susceptibility.
Previously reportedmutations involving codon 88 were not
found in our strains. Double mutations in gyrA, while not
uncommon in the isolates obtained through antimicrobial
Table 2 – Sequencing results of quinolone resistance-determining region fragments in the studied resistant clinical isolates.
Isolate No. OFLXR 89 GAC, D 90 GCG, A 91 TCG, S 94 GAC, D 95 AGC, S PGG type Type of resistance
H 264 – – – – – – 3 Susceptible
H 232 – – – – – – 1 Susceptible
11T – – – – – Thr+ 2 MDR
2T – – – – – Thr+ 2 MDR
6T – – – – – Thr+ 2 MDR
1193 – – – – – Thr+ 2 MDR
1499 – – – – – Thr+ 1 MDR
3T – – – – – Thr+ 2 MDR
600 – – – – – Thr+ 2 MDR
194X + – – – + Thr+ 2 Resistant
12T + – – – + Thr+ 2 Resistant
12X + – +GTG – – Thr+ 2 Resistant
1207X + – – – – Thr+ 2 Resistant
3369X + – +GTG – – Thr+ 1 Resistant
1241X + – +GTG – + Thr+ 2 Resistant
124X + – +GTG – – Thr+ 2 Resistant
9T + – +GTG – – Thr+ 2 Resistant
571X + – – – – Thr+ 3 Resistant
4T + – – – + Thr+ 1 Resistant
662X + – – – – Thr+ 3 Resistant
7115X + – – – – Thr+ 1 Resistant
117X + – – – – Thr+ 1 Resistant
568X + – – – – Thr+ 1 Resistant
115X + – ACG – + Thr+ 2 Resistant
665X + – ACG – + Thr+ 2 Resistant
60X + – – – + Thr+ 1 Resistant
7211X + – – – – Thr+ 1 Resistant
535yev + – +GTG – + Thr+ 2 Resistant
552yev + – – – + Thr+ 1 Resistant
543yev + – – – + Thr+ 2 Resistant
534yev + – +GTG – – Thr+ 2 Resistant
3562 + – – – + Ser 3 Resistant
3510 + – – – + Thr+ 2 Resistant
3491 + – – – + Thr+ 1 Resistant
3368 + – – – + Thr+ 2 Resistant
3309 + – + – + Thr+ 2 Resistant
3432 + – + – + Thr+ 1 Resistant
3382 + – + – + Thr+ 1 Resistant
3538 + – + – + Thr+ 1 Resistant
3613 + – – – + Thr+ 1 Resistant
3413 + – – – + Thr+ 2 Resistant
3632 + – – – + Thr+ 1 Resistant
3540 + – – – + Thr+ 1 Resistant
3645 + – + – + Thr+ 1 Resistant
3477 + – + – – Thr+ 2 Resistant
3433 + – + – – Ser 3 Resistant
3517 + – + – – Thr+ 2 Resistant
3565 + – + – + Thr+ 1 Resistant
3365 + – + – + Thr+ 1 Resistant
3515 + – + – – Thr+ 2 Resistant
H37RV – – – – – Ser 3 Susceptible
Note: Ofloxacin-susceptible strains (ofloxacin minimum inhibitory concentration < 2 mg/L) as susceptible and multi-drug resistant isolates.
Ofloxacin–resistant isolates without gyrA mutations (ofloxacin minimum inhibitory concentration > 2 mg/L). Ofloxacin-resistant isolates with
gyrA mutations (ofloxacin minimum inhibitory concentration > 2 mg/L). gyrA95: AGC? ACC (Ser? Thr).
MDR = multi-drug resistance; OFLXr = ofloxacin resistance; PGG = principal genetic group.
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[6,12–15].
The results of nucleotide sequencing of gyrA QRDRs were
analyzed for 42 isolates resistant to ofloxacin (20 isolates from
Iran and 22 from Belarus). Studying the molecular basis of
resistance in drug-resistant clinical isolates of M. tuberculosisto fluoroquinolone drugs has identified mutations in QRDR
of the gyrA gene from isolates of M. tuberculosis.
Genotyping allows the identification and characteristic
descriptions of isolates circulating in different regions,
groups, and ways to track the spread of resistant and more
virulent variants. Development of drug resistance is directly
Fig. 2 – Nucleotide sequence and types of missense mutations within the quinolone resistance-determining region of the
gyrA gene of resistant isolates.
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for the treatment of TB. Ultimately, the selection of mutant
isolates and their rapid accumulation in the population,
determines the spread of resistance to drugs.
Other than mutations affecting gyrA and fluoroquinolone
resistance, there are other mechanisms including efflux
pumps, decreased cell-wall permeability to drugs, and per-
haps drug inactivation. Fluoroquinolone resistance can rarely
be associated with gyrB mutations and may be a probable
efflux mechanism. There is a natural polymorphism in codon
95 in the sequences of gyrA that is not associated with resis-
tance that occurs in both fluoroquinolone-sensitive and
fluoroquinolone-resistant bacteria. Fluoroquinolone drugs
are broad-spectrum antibiotics for the treatment of undiag-
nosed infections. For this reason there is concern about the
levels of fluoroquinolone-resistant TB in regions with high
drug resistance rates.
In the absence of antibiotics, the resistant forms will be
replaced by more viable susceptible mycobacteria. However,
in patients receiving anti-TB drugs, resistant bacteria often
survive. Thus, the presence of mutations does not impair via-
bility, as well as compensatory evolution suggests that
antibiotic-resistant bacteria will persist in the population,
even if it applied the policy of rational use of antimicrobials.
Based on the above, we conclude that the determination of
the amino acid sequence regions, which determine resistance
to quinolone (QRDRs) in the subunit-a of the DNA gyrase gene
could be used as a molecular marker of mycobacterial resis-
tance to fluoroquinolones.
Mycobacteria do not have an outer membrane comparable
to that of gram-negative bacteria, but the cell wall contains a
very complex lipid bilayer on the surface, which probably acts
like an outer membrane and limits the penetration of many
antimicrobial agents. Fluoroquinolones are relatively lipophi-
lic drugs, and their penetration appears to be mainly through
the lipid domains of mycobacterial cell walls.
Our findings confirm that 26% of isolates belonged to
PGG1. It is assumed that PGG1 is evolutionarily older than
other groups and the classification referred to the strain
Beijing from a subgroup of Genetic Group 1. It was found that
these strains caused outbreaks of infection.
Conclusion
In conclusion, a relationship between phenotypic resistance
to fluoroquinolones and mutations in QRDRs were detected
among M. tuberculosis clinical isolates of Belarus and Iran.
However, frequencies in gyrA codons in Belarus and Iran weresimilar, therefore it is not of geographical concern for the two
countries.
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